{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:28:03Z","timestamp":1794032883945,"version":"4.8.0"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.03096","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T23:29:43Z","timestamp":1579044583000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":173,"title":["IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications"],"prefix":"10.3389","volume":"10","author":[{"given":"Esther","family":"von Stebut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Thaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Sch\u00e4ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCHEARTFAILURE.114.001152","article-title":"Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish Nationwide Cohort study","volume":"7","author":"Kristensen","year":"2014","journal-title":"Circ Heart Fail."},{"key":"B4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/j.1365-2133.2007.08190.x","article-title":"Psoriasis patients show signs of insulin resistance","volume":"157","author":"Boehncke","year":"2007","journal-title":"Br J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1073\/pnas.91.11.4854","article-title":"Tumor necrosis factor alpha inhibits signaling from the insulin receptor","volume":"91","author":"Hotamisligil","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J Clin Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.it.2010.03.001","article-title":"Innate immunity and adipose tissue biology","volume":"31","author":"Sch\u00e4ffler","year":"2010","journal-title":"Trends Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat Rev Drug Discov."},{"key":"B13","unstructured":"Global Report on Psoriasis.2016"},{"key":"B14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI90 response: the new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10067-010-1504-5","article-title":"An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)","volume":"29","author":"Jung","year":"2010","journal-title":"Clin Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-derived IL-17E contributes to inflammation in psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jid.2019.01.026","article-title":"Psoriasis pathogenesis: keratinocytes are back in the spotlight","volume":"139","author":"Garzorz-Stark","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.jid.2019.01.021","article-title":"IL-17E (IL-25) enhances innate immune responses during skin inflammation","volume":"139","author":"Senra","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13238-011-1006-5","article-title":"Structure and function of interleukin-17 family cytokines","volume":"2","author":"Zhang","year":"2011","journal-title":"Protein Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.688","article-title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis","volume":"42","author":"Huffmeier","year":"2010","journal-title":"Nat Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J Exp Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/pathogens4020406","article-title":"Oropharyngeal candidiasis in HIV infection: analysis of impaired mucosal immune response to candida albicans in mice expressing the HIV-1 transgene","volume":"4","author":"de Repentigny","year":"2015","journal-title":"Pathogens."},{"key":"B29","volume-title":"Cellular and Molecular Immunology.","author":"Abbas","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/bjd.15358","article-title":"IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin","volume":"177","author":"Brembilla","year":"2017","journal-title":"Br J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1365-2133.2008.08769.x","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis - results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/ddg.13516","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update - short version part 1 - Systemic treatment","volume":"16","author":"Nast","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled transfigure trial","volume":"181","author":"Reich","year":"2018","journal-title":"Br J Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaad.2019.05.082","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"30","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","article-title":"Brodalumab for the treatment of psoriasis: a review of phase III trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","article-title":"Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study","volume":"81","author":"Torres","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/j.1365-2133.2008.08759.x","article-title":"Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis","volume":"159","author":"Kaur","year":"2008","journal-title":"Br J Dermatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/exd.12381","article-title":"Cardiovascular biomarkers in patients with psoriasis","volume":"23","author":"Gerdes","year":"2014","journal-title":"Exp Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjd.14013","article-title":"Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission","volume":"174","author":"Coimbra","year":"2016","journal-title":"Br J Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/09546634.2018.1506081","article-title":"No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis","volume":"30","author":"Bokor-Billmann","year":"2019","journal-title":"J Dermatolog Treat."},{"key":"B63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaad.2018.02.027","article-title":"Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"79","author":"Loos","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/archderm.1973.01620210078025","article-title":"Thromboembolic disorders associated with psoriasis","volume":"107","author":"McDonald","year":"1973","journal-title":"JAMA Dermatology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/B:EJEP.0000020447.59150.f9","article-title":"Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients","volume":"19","author":"Mallbris","year":"2004","journal-title":"Eur J Epidemiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"JAMA Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.0022-202X.2005.23681.x","article-title":"Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case\u2013control study","volume":"125","author":"Naldi","year":"2005","journal-title":"J Invest Dermatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case\u2013control study","volume":"157","author":"Gisondi","year":"2007","journal-title":"Br J Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/archderm.141.12.1527","article-title":"Impact of obesity and smoking on psoriasis presentation and management","volume":"141","author":"Herron","year":"2005","journal-title":"JAMA Dermatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2190\/PM.41.4.f","article-title":"Anxiety disorders, hypertension, and cardiovascular risk: a review","volume":"41","author":"Player","year":"2011","journal-title":"Int J Psychiatry Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-4632.2011.05071.x","article-title":"Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments","volume":"51","author":"Rieder","year":"2012","journal-title":"Int J Dermatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pde.12205","article-title":"Childhood psoriasis \u2014 an analysis of German health insurance data","volume":"31","author":"Matusiewicz","year":"2014","journal-title":"Pediatr Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1084\/jem.20031482","article-title":"Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha","volume":"199","author":"Boyman","year":"2004","journal-title":"J Exp Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11926-013-0377-4","article-title":"Mechanistic insights from animal models of psoriasis and psoriatic arthritis","volume":"15","author":"Weitz","year":"2013","journal-title":"Curr Rheumatol Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/jid.2013.404","article-title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions","volume":"134","author":"Croxford","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jdermsci.2017.06.010","article-title":"IL-17 for therapy","volume":"87","author":"Kurschus","year":"2017","journal-title":"J Dermatol Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11883-017-0692-8","article-title":"Emerging associations between neutrophils, atherosclerosis, and psoriasis","volume":"19","author":"Sanda","year":"2017","journal-title":"Curr Atheroscler Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijcard.2011.06.112","article-title":"Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis","volume":"151","author":"Avgerinou","year":"2011","journal-title":"Int J Cardiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jbspin.2014.02.005","article-title":"Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study","volume":"81","author":"Ramonda","year":"2014","journal-title":"Joint Bone Spine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11739-010-0458-6","article-title":"Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients","volume":"5","author":"Mazzoccoli","year":"2010","journal-title":"Intern Emerg Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10554-010-9616-1","article-title":"Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis","volume":"26","author":"Inaba","year":"2010","journal-title":"Int J Cardiovasc Imaging."},{"key":"B88","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","article-title":"Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2174\/1389450117666161229142155","article-title":"The two faces of interleukin-17A in atherosclerosis","volume":"18","author":"Akhavanpoor","year":"2017","journal-title":"Curr Drug Targets."},{"key":"B92","doi-asserted-by":"publisher","first-page":"154089","DOI":"10.1016\/j.cyto.2017.06.016","article-title":"Interleukin 17A in atherosclerosis-regulation and pathophysiologic effector function","volume":"122","author":"Nordlohne","year":"2017","journal-title":"Cytokine"},{"key":"B93","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.autrev.2017.07.009","article-title":"Effects of Interleukin 17 on the cardiovascular system","volume":"16","author":"Robert","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1139\/cjpp-2016-0664","article-title":"The role of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques","volume":"95","author":"Rai","year":"2017","journal-title":"Can J Physiol Pharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature11868","article-title":"Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells","volume":"496","author":"Kleinewietfeld","year":"2013","journal-title":"Nature."},{"key":"B98","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice","volume":"183","author":"Erbel","year":"2009","journal-title":"J Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.4049\/jimmunol.1000116","article-title":"A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice","volume":"185","author":"Gao","year":"2010","journal-title":"J Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.109.924886","article-title":"Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1161\/ATVBAHA.111.227629","article-title":"Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice","volume":"31","author":"Madhur","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/ATVBAHA.111.229997","article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice","volume":"32","author":"Danzaki","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.109.213157","article-title":"Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy","volume":"106","author":"Baldeviano","year":"2010","journal-title":"Circ Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1084\/jem.20132126","article-title":"Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy","volume":"211","author":"Wu","year":"2014","journal-title":"J Exp Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.4049\/jimmunol.180.4.2686","article-title":"CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis","volume":"180","author":"Valaperti","year":"2008","journal-title":"J Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/CIRCRESAHA.112.300666","article-title":"Neutrophil-derived cathelicidin promotes adhesion of classical monocytes","volume":"112","author":"Wantha","year":"2013","journal-title":"Circ Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/intimm\/dxs056","article-title":"IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCbeta\/Erk1\/2\/NF-kappaB-dependent signaling pathway","volume":"24","author":"Liu","year":"2012","journal-title":"Int Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s10875-009-9355-z","article-title":"Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis","volume":"30","author":"Yuan","year":"2010","journal-title":"J Clin Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.4049\/jimmunol.1400181","article-title":"IL-17A influences essential functions of the monocyte\/macrophage lineage and is involved in advanced murine and human atherosclerosis","volume":"193","author":"Erbel","year":"2014","journal-title":"J Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.108.827618","article-title":"Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells","volume":"119","author":"Eid","year":"2009","journal-title":"Circulation."},{"key":"B112","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/path.2667","article-title":"Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques","volume":"220","author":"de Boer","year":"2010","journal-title":"J Pathol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1160\/TH12-06-0425","article-title":"Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction","volume":"109","author":"de Boer","year":"2013","journal-title":"Thromb Haemost."},{"key":"B114","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension."},{"key":"B115","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12944-017-0588-1","article-title":"IL-17-differentiated macrophages secrete pro-inflammatory cytokines in response to oxidized low-density lipoprotein","volume":"16","author":"de la Paz Sanchez-Martinez","year":"2017","journal-title":"Lipids Health Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J Exp Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur Heart J."},{"key":"B118","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.atherosclerosis.2013.07.057","article-title":"Tumor necrosis factor-alpha inhibition improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women","volume":"230","author":"Moreau","year":"2013","journal-title":"Atherosclerosis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2010.08.002","article-title":"Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases","volume":"25","author":"Straub","year":"2011","journal-title":"Brain Behav Immun"},{"key":"B122","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tem.2011.12.003","article-title":"CTRP family: linking immunity to metabolism","volume":"23","author":"Sch\u00e4ffler","year":"2012","journal-title":"Trends Endocrinol Metab."},{"key":"B123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fendo.2013.00052","article-title":"Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies","volume":"4","author":"McArdle","year":"2013","journal-title":"Front Endocrinol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nri3071","article-title":"Macrophage-mediated inflammation in metabolic disease","volume":"11","author":"Chawla","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet."},{"key":"B126","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.4049\/jimmunol.1001269","article-title":"IL-17 regulates adipogenesis, glucose homeostasis, and obesity","volume":"185","author":"Zuniga","year":"2010","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.4049\/jimmunol.1002615","article-title":"Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes","volume":"186","author":"Jagannathan-Bogdan","year":"2011","journal-title":"J Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"366-374 e361","DOI":"10.1053\/j.gastro.2013.04.010","article-title":"Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals","volume":"145","author":"Fabbrini","year":"2013","journal-title":"Gastroenterology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1038\/ncomms5602","article-title":"HGK\/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance","volume":"5","author":"Chuang","year":"2014","journal-title":"Nat Commun."},{"key":"B131","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch Dermatol Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","article-title":"Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies","volume":"68","author":"Armstrong","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdermsci.2008.04.016","article-title":"Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population","volume":"52","author":"Jin","year":"2008","journal-title":"J Dermatol Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/archderm.144.12.1571","article-title":"Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome","volume":"144","author":"Chen","year":"2008","journal-title":"Arch Dermatol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","article-title":"The concept of psoriasis as a systemic inflammation: implications for disease management","volume":"26","author":"Reich","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.3390\/jcm6070068","article-title":"Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases","volume":"6","author":"Chehimi","year":"2017","journal-title":"J Clin Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbrc.2016.06.049","article-title":"IL-17A synergistically enhances TNFalpha-induced IL-6 and CCL20 production in 3T3-L1 adipocytes","volume":"477","author":"Shinjo","year":"2016","journal-title":"Biochem Biophys Res Commun."},{"key":"B142","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10529-010-0440-4","article-title":"IL-17A promotes transdifferentiation of mouse myoblast cells (C2C12) into adipocytes by increasing the expression of peroxisome proliferator-activated receptor gamma through CAAT\/enhancer binding protein beta signaling","volume":"33","author":"Lee","year":"2011","journal-title":"Biotechnol Lett."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.bcp.2009.03.008","article-title":"Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes","volume":"77","author":"Shin","year":"2009","journal-title":"Biochem Pharmacol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.imlet.2017.02.004","article-title":"IL-17 axis accelerates the inflammatory progression of obese in mice via TBK1 and IKBKE pathway","volume":"184","author":"Lee","year":"2017","journal-title":"Immunol Lett."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/db13-1511","article-title":"T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes","volume":"63","author":"Dalmas","year":"2014","journal-title":"Diabetes."},{"key":"B146","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/HYPERTENSIONAHA.111.183178","article-title":"Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance","volume":"59","author":"Ohshima","year":"2012","journal-title":"Hypertension."},{"key":"B147","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdermsci.2013.12.013","article-title":"VEGF-A promotes IL-17A-producing gammadelta T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells","volume":"74","author":"Suzuki","year":"2014","journal-title":"J Dermatol Sci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/exd.13467","article-title":"Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation, and associated comorbidities","volume":"27","author":"Krueger","year":"2017","journal-title":"Exp Dermatol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-014-0042-5","article-title":"Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy","volume":"4","author":"Gisondi","year":"2014","journal-title":"Dermatol Ther."},{"key":"B150","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2014.00368","article-title":"Relationships between adipose tissue and psoriasis, with or without arthritis","volume":"5","author":"Toussirot","year":"2014","journal-title":"Front Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/09546634.2014.907466","article-title":"Differential management of mild-to-severe psoriasis with biologic drugs: an Italian Delphi consensus expert panel","volume":"26","author":"Girolomoni","year":"2015","journal-title":"J Dermatolog Treat."},{"key":"B152","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","article-title":"Anti-il-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"17","author":"Canavan","year":"2016","journal-title":"Am J Clin Dermatol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/1744666X.2016.1112739","article-title":"Interleukin 17-A inhibition in the treatment of psoriasis","volume":"12","author":"Yiu","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/2229-5178.198765","article-title":"Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study","volume":"8","author":"Bhat","year":"2017","journal-title":"Indian Dermatol Online J."},{"key":"B155","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T23:48:05Z","timestamp":1695599285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":156,"alternative-id":["10.3389\/fimmu.2019.03096"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.03096","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"article-number":"3096"}}